miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164

Shi,Jia-Ang; Lu,Da-Lin; Huang,Xuan; Tan,Wei

doi:10.3892/ijmm.2014.1749

miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164

Authors:
- Jia-Ang Shi
- Da-Lin Lu
- Xuan Huang
- Wei Tan
View Affiliations

Affiliations: Department of Psychiatry, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, P.R. China, Medical College, Nanchang University, Jiangxi 330000, P.R. China
Published online on: April 22, 2014 https://doi.org/10.3892/ijmm.2014.1749
Pages: 237-243

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is known that microRNA-219 (miR-219) expression is downregulated in medulloblastoma. In the present study, we investigated the expression, targets and functional effects of miR-219 in D283-MED medulloblastoma cells. We first demonstrated that miR-219 not only inhibits proliferation, but also suppresses the invasion and migration of D283-MED cells. Moreover, the knockdown of miR-219 promoted the proliferation, migration and invasion of the D283-MED cells. Secondly, we predicted that miR-219 targets the 3' untranslated region (3'UTR) of CD164 and orthodenticle homeobox 2 (OTX2) and then confirmed that it significantly downregulated the protein expression of CD164 and OTX2 in D283-MED cells. Finally, we demonstrated that the proliferation, invasion and migration of D283-MED cells were promoted by theectopic expression of CD164. These results indicate that miR-219 suppresses the proliferation, migration and invasion of medulloblastoma cells by targeting CD164. The results also suggest that miR-219 may serve as a potential therapeutic agent for medulloblastoma.

View Figures

View References

1	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar
2	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
3	Crawford JR, MacDonald TJ and Packer RJ: Medulloblastoma in childhood: new biological advances. Lancet Neurol. 6:1073–1085. 2007. View Article : Google Scholar : PubMed/NCBI
4	Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 17:832–845. 1999.PubMed/NCBI
5	Doyonnas R, Yi-Hsin Chan J, Butler LH, et al: CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptor. J Immunol. 165:840–851. 2000. View Article : Google Scholar : PubMed/NCBI
6	Tang J, Zhang L, She X, et al: Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo. Cancer Invest. 30:380–389. 2012. View Article : Google Scholar : PubMed/NCBI
7	Havens AM, Jung Y, Sun YX, et al: The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer. 6:1952006. View Article : Google Scholar : PubMed/NCBI
8	Adamson DC, Shi Q, Wortham M, et al: OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 70:181–191. 2010. View Article : Google Scholar : PubMed/NCBI
9	Luo XG, Zou JN, Wang SZ, Zhang TC and Xi T: Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life. 62:194–199. 2010.PubMed/NCBI
10	Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 144:4562–4574. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sethupathy P, Megraw M and Hatzigeorgiou AG: A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods. 3:881–886. 2006. View Article : Google Scholar : PubMed/NCBI
12	Venkataraman S, Alimova I, Fan R, et al: MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One. 5:e107482010. View Article : Google Scholar : PubMed/NCBI
13	Weeraratne SD, Amani V, Teider N, et al: Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 123:539–552. 2012. View Article : Google Scholar : PubMed/NCBI
14	Garzia L1, Andolfo I, Cusanelli E, et al: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One. 4:e49982009. View Article : Google Scholar : PubMed/NCBI
15	Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, Kool M, Northcott PA, Jugold M, Bazhin AV, Eichmüller SB, Kulozik AE, Pscherer A, Benner A, Taylor MD, Pomeroy SL, Kemkemer R, Witt O, Korshunov A, Lichter P and Pfister SM: MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 123:529–538. 2012. View Article : Google Scholar : PubMed/NCBI
16	Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD, Foreman NK and Vibhakar R: MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem. 288:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
17	Grunder E, D’Ambrosio R, Fiaschetti G, Abela L, Arcaro A, Zuzak T, Ohgaki H, Lv SQ, Shalaby T and Grotzer M: MicroRNA-21 suppression impedes medulloblastoma cell migration. Eur J Cancer. 47:2479–2490. 2011. View Article : Google Scholar : PubMed/NCBI
18	Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS and Ng HK: MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 23:413–425. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L, Chen Z and Ng HK: miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol. 40:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI
20	Dugas JC, Cuellar TL, Scholze A, Ason B, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT and Barres BA: Dicer1 and miR-219 are required for normal oligodendrocyte differentiation and myelination. Neuron. 65:597–611. 2010. View Article : Google Scholar : PubMed/NCBI
21	Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D and Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 586:884–891. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I and Gulino A: MicroRNA profiling in human MB. Int J Cancer. 124:568–577. 2009. View Article : Google Scholar